Key Highlights
- ARK Invest acquired approximately 281,000 shares of CRSP stock valued at roughly $14.82M following a 10% decline
- CRISPR Therapeutics’ stock drop followed the announcement of a $350M private placement
- CRSP ranks as ARK’s second-biggest holding portfolio-wide, representing approximately $500M in total value
- ARK reduced stakes in 10x Genomics (TXG) and Teradyne (TER) during portfolio rebalancing
- Both Seeking Alpha Quant ratings and Wall Street analyst consensus indicate a Buy rating for CRSP
Shares of CRISPR Therapeutics (CRSP) tumbled approximately 10% following the biotech company’s disclosure of a $350M private placement. Cathie Wood’s ARK Invest capitalized on the decline, scooping up shares at the reduced price.
The investment firm acquired roughly 281,000 shares of CRSP stock distributed across its various ETFs, representing a combined investment of approximately $14.82M. ARK disclosed these transactions in its daily trade summary dated March 11, 2026.
This purchase aligns with ARK’s recent strategy. During the fourth quarter of 2025, Wood expanded ARK’s position in CRSP by 7.5%, purchasing around 735,000 shares. The most recent acquisition extends this bullish trajectory.
CRSP stock now represents ARK’s second-most significant position when considering all combined ETF holdings, accounting for a 4.49% weighting and approximately $500M in aggregate exposure. This constitutes a substantial commitment to a company still in its pre-revenue phase.
Private Placement Triggers Investor Concern
The sharp 10% decline materialized after CRISPR Therapeutics revealed plans for a $350M private placement. Such capital raises typically dilute current shareholders’ ownership stakes, commonly resulting in near-term price pressure.
The fundraising announcement shouldn’t come as a complete surprise. With zero revenue generation and negative operational margins, CRISPR Therapeutics relies on capital infusions to advance its developmental pipeline — a standard approach for companies at this development stage.
However, the company maintains robust financial fundamentals. With a current ratio of 13.32 and a debt-to-equity ratio of just 0.11, CRISPR Therapeutics demonstrates exceptional liquidity and minimal leverage.
This financial stability likely contributed to ARK’s confidence in adding to its position during the price weakness.
CRSP’s Pipeline and Products
CRISPR Therapeutics’ inaugural approved treatment, Casgevy, resulted from a collaboration with Vertex Pharmaceuticals and addresses sickle-cell disease and transfusion-dependent beta-thalassemia.
The company’s pipeline extends beyond Casgevy, encompassing programs in immuno-oncology, cardiovascular therapeutics, and stem cell-derived treatments for Type 1 diabetes.
CRISPR Therapeutics currently carries a market capitalization of approximately $5.07 billion according to recent data.
Recent insider transaction patterns lean decidedly toward selling — five separate insider dispositions over the previous three months totaling 163,751 shares, with zero insider purchases during that period.
Portfolio Adjustments Across ARK’s Holdings
While accumulating CRSP shares, ARK simultaneously reduced exposure elsewhere in its portfolio. The firm liquidated 78,412 shares of 10x Genomics (TXG) valued at approximately $1.60M and disposed of 21,505 shares of Teradyne (TER) worth $6.47M.
These dispositions appear consistent with standard portfolio rebalancing practices across ARK’s actively managed ETF suite, rather than signaling negative sentiment toward those specific companies.
Regarding analyst perspectives, CRSP stock carries a Buy recommendation from both Seeking Alpha’s Quant rating system and the Wall Street analyst community. The Quant methodology particularly highlights strong grades for growth potential and momentum factors.
A Seeking Alpha analyst highlighted Casgevy’s market introduction and the company’s substantial cash position as notable strengths, while acknowledging the inherent uncertainties associated with pre-revenue biotechnology investments.
GuruFocus’s GF Value assessment currently classifies CRSP as substantially overvalued, calculating a fair value of $16.13, which stands in contrast to the prevailing bullish analyst outlook.
CRSP stock concluded trading down approximately 10.17% on the session when the offering was publicly announced.
